AACR in 30 Seconds: CAR-T promise, Merck’s new move, rural health

The AACR meeting continues to provide groundbreaking insights into the latest advancements in cancer research. Today’s highlights include a closer look at a drug recently acquired by Merck from China, a potentially controversial application of CAR-T therapy, and a discussion on the geographical disparities in American oncology. As the conference progresses, attendees can look forward to a live event in San Diego on Tuesday night and a virtual recap of the AACR conference on Thursday.

One of the most intriguing presentations at the conference involved a study conducted at the Dana-Farber Cancer Institute focusing on smoldering multiple myeloma. In this early phase trial, 20 high-risk patients with smoldering multiple myeloma were treated with Carvykti, a BCMA-directed CAR-T therapy. The goal of the study was to evaluate the efficacy of immunotherapy in preventing the progression of multiple myeloma in patients at a high risk of developing the active cancer.

Unfortunately, further details of this study are restricted to STAT+ subscribers. To access the full article and gain in-depth analysis, newsletters, premium events, and news alerts, readers are encouraged to subscribe to STAT+. This exclusive content offers valuable insights into the latest advancements in cancer research and treatment.

As the AACR meeting continues, researchers and healthcare professionals are excited to learn more about the innovative approaches being explored in the field of oncology. From novel drug acquisitions to cutting-edge therapies like CAR-T, the conference sheds light on the diverse and evolving landscape of cancer treatment. Stay tuned for more updates and insights from the AACR meeting as researchers strive to improve outcomes for cancer patients worldwide.